“Unacceptable”: Prominent U.S. Senators Demand FDA Provide Names of Troubled Foreign Drugmakers Skirting Import Bans

Breaking News: U.S. Senators Demand FDA Disclose Names of Troubled Foreign Drugmakers Two prominent U.S. senators, Rick Scott (R-Fla.) and Kirsten Gillibrand (D-N.Y.), have issued a joint statement demanding the Food and Drug Administration (FDA) provide an immediate accounting of foreign generic drugmakers allowed to skirt import bans meant to keep dangerous medication out of the United States. Timeline: September 19, 2025: Senators Scott and Gillibrand issue joint statement Recent ProPublica investigation reveals FDA oversight concerns FDA has yet to respond to senators' demands Immediate Impact: The senators' demand comes in response to a recent ProPublica investigation that raised urgent concerns about the FDA's oversight of foreign drugmakers. The investigation found that some foreign generic drugmakers are exploiting loopholes to import medications into the U.S., despite being banned due to safety concerns. Background Context: The FDA has faced criticism for its handling of foreign generic drugmakers, with many arguing that the agency is not doing enough to ensure the safety and efficacy of imported medications. The issue has gained international attention, with some countries imposing stricter regulations on pharmaceutical imports. What Happens Next: The FDA has yet to respond to the senators' demands, but sources indicate that the agency may provide a list of troubled foreign drugmakers in the coming days. The senators have vowed to continue pressing for greater transparency and accountability from the FDA, citing the need for urgent action to protect public health. This breaking news story will be updated as more information becomes available. *This story is developing. Information compiled from Propublica reporting.*